SalubrisBio

What SalubrisBio does

SalubrisBio (legal name Salubris Biotherapeutics, Inc.) is a clinical-stage biotechnology company founded in August 2016 as a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., a China-based pharmaceutical company. The company is headquartered in Gaithersburg, Maryland, with an additional office at the Cambridge Innovation Center in Cambridge, Massachusetts, and operates with 11–50 employees. Its sole investor and parent has provided over $100 million in funding across three tranches ($32M in March 2022, $35M in March 2023, and $35M in April 2024).

The company is developing a portfolio of three clinical-stage complex biologic therapeutics. JK07 is a recombinant antibody fusion protein composed of an NRG-1 polypeptide fused to a fully human IgG1 monoclonal antibody targeting ErbB3; it selectively stimulates the ErbB4 pathway while blocking HER3 to treat heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF), and is currently in Phase 2 (RENEU-HF trial) with expansion into Group 2 pulmonary hypertension (RENEU-PH). JK06 is a first-in-class quadrivalent, biparatopic antibody-drug conjugate targeting the 5T4 oncofetal antigen with an MMAE payload, currently in Phase 1/2 for solid tumors. JK08 is a recombinant fusion combining a CTLA-4-specific antibody with an IL-15 fusion domain to combine checkpoint inhibition with NK cell activation in solid tumors, also in Phase 1/2.

SalubrisBio has no marketed products and generates no commercial revenue. Its business model is preclinical and clinical-stage R&D, funded entirely by corporate parent equity contributions, with value creation expected through eventual commercialization, partnership, or acquisition of its novel biologic assets. Clinical trial operations span the United States and Europe (UK, Belgium, Spain) via collaborations with academic centers including Cleveland Clinic, Jules Bordet Institute, Vall d'Hebron Institute of Oncology, and NEXT Oncology. The company addresses two large patient populations—approximately 6.7 million Americans and 64 million people worldwide living with heart failure, plus broad solid tumor populations expressing 5T4—with disease-modifying potential in indications where current standard of care remains inadequate.

Name

SalubrisBio

Legal name

Salubris Biotherapeutics, Inc.

Website

https://salubrisbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

SalubrisBio is a clinical-stage biotechnology company developing novel antibody fusion proteins and antibody-drug conjugates for heart failure (JK07) and solid tumors (JK06, JK08). It is a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Antibody therapeutics
• Antibody-drug conjugates
• Fusion proteins
• Cardiovascular biologics
• Oncology biologics

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Core offering

SalubrisBio is a clinical-stage biotechnology company developing a portfolio of novel antibody fusion proteins and antibody-drug conjugates (ADCs) for cardiovascular disease and oncology. Its pipeline includes JK07, an NRG-1/ErbB4 selective agonist antibody fusion protein in Phase 2 for heart failure; JK08, an IL-15/CTLA-4 antibody fusion in Phase 1/2 for solid tumors; and JK06, a first-in-class 5T4-targeted biparatopic ADC in Phase 1/2 for solid tumors. The company has no commercially marketed products; all candidates are investigational biologics in active clinical development.

Product overview

SalubrisBio is a clinical-stage biotechnology company developing a portfolio of novel complex biologic therapeutics targeting cardiovascular disease and oncology. The company's pipeline consists of three clinical-stage assets: JK07 is an NRG1-ErbB3 antibody fusion protein for heart failure (HFrEF and HFpEF), JK08 is an IL15-CTLA4 antibody fusion for solid tumors, and JK06 is a 5T4-targeted biparatopic ADC for solid tumors. JK07 is the company's lead cardiovascular candidate in Phase 2, while JK06 and JK08 are in Phase 1/2 oncology trials.

Differentiator

Problem solved

Functional benefit

Products and services

• JK07 JK07 is a recombinant antibody fusion protein consisting of an active polypeptide fragment of neuregulin-1 (NRG-1) and a fully human IgG1 monoclonal antibody targeting ErbB3. It selectively stimulates the ErbB4 pathway while blocking the HER3/ErbB3 pathway to widen the therapeutic window. JK07 is being developed for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), and is in Phase 2 (RENEU-HF) and Phase 2a (RENEU-PH) clinical trials.
• JK08 JK08 is a recombinant fusion protein consisting of a CTLA-4-specific antibody and an IL-15 fusion domain. It is designed to synergistically combine CTLA-4 targeting with IL-15 immune stimulation for the treatment of solid tumors, with the goal of depleting T-regulatory cells and reversing immunosuppression. JK08 has shown dose-dependent pharmacodynamic activity with NK and CD8+ T cell induction and is in Phase 1/2 clinical development.
• JK06 JK06 is a first-in-class quadrivalent, biparatopic antibody-drug conjugate (ADC) that selectively targets 5T4—an oncofetal protein overexpressed in lung, breast, renal, and genitourinary cancers—with an MMAE payload. JK06 has demonstrated picomolar affinity for 5T4 and rapid internalization due to its biparatopic design, and is in Phase 1/2 clinical trials for solid tumors including non-small cell lung cancer and breast cancer. As of May 2026, 173 patients had been treated across the JK06 Phase 1/2 study with no Grade 4 or 5 TRAEs reported.

Quantifiable outcome

• JK07 Phase 1b: 49% average relative improvement in ejection fraction at 6 months following single dose at 0.09 mg/kg
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Cleveland CliniccoreOthersCleveland Clinic serves as a clinical research site for JK07 heart failure trials. Dr. W.H. Wilson Tang, Research Director for the Section of Heart Failure and Cardiac Transplant Medicine at Cleveland Clinic, is a lead investigator and has presented clinical data from JK07 trials.
• Jules Bordet InstitutecoreOthersDr. Nuria Kotecki from Jules Bordet Institute in Brussels serves as an investigator for JK06 clinical trials and has provided expert commentary on the 5T4 target and therapeutic potential.
• Vall d'Hebron Institute of Oncology (VHIO)coreOthersDr. Omar Saavedra from VHIO in Barcelona presented JK06 expansion cohort data at AACR 2026 and serves as an investigator in the JK06 Phase 1/2 study.
• New Experimental Therapeutics (NEXT) OncologyminorOthersDr. Omar Saavedra from NEXT Oncology at Hospital Universitario Quironsalud Barcelona serves as an investigator and presenter for JK06 ASCO 2026 data.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca: Global pharmaceutical company with major cardiovascular (Farxiga/Dapagliflozin for HF) and oncology ADC franchises (Enhertu with Daiichi). Comparable to SalubrisBio's combined HF and ADC oncology focus; multiple SalubrisBio executives came from MedImmune/AstraZeneca.
• Bristol Myers Squibb: Global pharmaceutical company with significant cardiovascular and oncology biologics portfolios (e.g., Sotyktu, Opdivo). SalubrisBio's CMO previously led Sotyktu development at BMS; comparable as broad incumbent in the same therapeutic categories where SalubrisBio's assets compete.

Direct peers

• Zymeworks: Clinical-stage biotech developing multispecific antibody therapeutics including Azymetric bispecific platform and zanidatamab. Comparable to SalubrisBio's multispecific antibody-fusion approach and oncology pipeline breadth.
• Adagene: Clinical-stage oncology company developing bispecific and multispecific antibodies with proprietary PowerBody and SAFEbody platforms. Comparable to JK06 and JK08 given similar multispecific antibody engineering approach and solid tumor focus.
• Cytokinetics: Clinical-stage cardiovascular company developing cardiac myosin activators (e.g., omecamtiv mecarbil, aficamten) for heart failure. Most directly comparable to SalubrisBio's JK07 heart failure program, with similar Phase 2/3 development stage and patient population focus.
• Tenaya Therapeutics: Genetic medicines company developing cardiac gene therapies and regenerative approaches for heart failure and cardiomyopathies. Directly comparable to JK07 as another clinical-stage company targeting disease modification in HFrEF/HFpEF.
• Mersana Therapeutics: Clinical-stage ADC company developing Dolasynthen and Immunosynthen platforms across solid tumors including NSCLC and breast cancer. Most comparable to JK06 given overlapping oncology indications (NSCLC, breast cancer) and ADC modality.
• Janux Therapeutics: Clinical-stage immuno-oncology company developing T cell engager (TCE) bispecific antibodies. Comparable to SalubrisBio's JK08 immunocytokine/dual-mechanism oncology biologics in targeting tumors with engineered multispecific antibody constructs.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs), a bispecific/multispecific ADC platform targeting tumor antigens with payload + immune stimulation. Directly comparable to SalubrisBio's JK06 biparatopic ADC strategy.

Emerging players

• Lexeo Therapeutics: Clinical-stage gene therapy company focused on cardiovascular diseases including Friedreich's ataxia cardiomyopathy and other cardiac genetic disorders. Comparable emerging cardiovascular biotech with similar biologic modality and unmet need focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/salubris-biotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SalubrisBio